Utilization of Hepatitis B Virus-Positive Allografts in Liver Transplantation: a New Arrow to the Bowstring for Expanding the Donor Pool?
Gang Xu,Chen-Hao Jiang,Yao Xiao,Tao Lyu,Li Jiang,Lyu-Nan Yan,Jia-Yin Yang
DOI: https://doi.org/10.21037/hbsn-21-543
2022-01-01
HepatoBiliary Surgery and Nutrition
Abstract:HepatoBiliary Surg Nutr 2022;11(2):283-287 | https://dx.doi.org/10.21037/hbsn-21-543 Liver disease accounts for approximately 2 million deaths per year worldwide, including 1 million due to complications of cirrhosis and 1 million due to viral hepatitis and hepatocellular carcinoma (HCC) (1). Liver transplantation (LTx) is the definitive management for end-stage liver disease and HCC in both children and adults. However, the number of liver transplant candidates on the waiting list exceeds that of available allografts. Approximately one-third of the global population has serological evidence of past or current hepatitis B virus (HBV) infection, including 250 million people with chronic HBV infection. The concept of using HBV-positive liver allografts has been implemented to expand the organ pool worldwide (2). Especially in regions with high or intermediate prevalence of HBV infection, these allografts can be an optimal choice for LTx recipients. Over the decades, LTx from HBV-exposed allografts has shifted from the first case in the 1980s to expanded practice supported by positive outcomes, particularly with the availability of safe and effective clinical therapies (3). Currently, both the American Society of Transplantation and the British Transplantation Society have developed consensus guidelines indicating that the utilization of liver allografts from HBV-positive donors is acceptable (4,5). To date, some early studies have investigated differences in the risk of HBV transmission from liver donors to recipients by serologic status (6-8). The results revealed that hepatitis B surface antigen (HBsAg)-positive liver donors were at a high risk of transmission, whereas anti-hepatitis B core (HBc)-positive/HBsAg-negative liver donors had a lower risk (6,7). In addition, given that HBV resides in the form of covalently closed circular DNA within the nucleus of hepatocytes, compared with other solid organ transplants such as the kidney and lung, LTx recipients have the highest risk of HBV transmission (9,10). Currently, the availability of clinical prophylactic therapies, such as hepatitis B immunoglobulin (HBIG), and long-term nucleos(t)ide analogues (NAs), such as entecavir and tenofovir, for suppressing HBV replication have been widely used in clinical treatment. Unlike hepatitis C virus infection, there is no direct antiviral drug for the treatment of HBV infection; however, the current treatments have allowed the application of HBV-positive allografts in LTx. In this context, Delman et al. reported the short-term outcomes of HBV nucleic acid test (HBV NAT)-positive liver allografts in HBV seronegative recipients in Annals of Surgery (10). In their prospective study, 33 LTx patients received HBV NAT-positive allografts and all recipients were HBV NAT-negative and HBsAg-negative at the time of LTx. With a median follow-up of 1 year, laboratory post-transplant monitoring per the protocol revealed that 9 (27.3%) LTx recipients had detectable HBV DNA on HBV NAT testing. At the end of the study period, 31 (93.9%) LTx recipients were HBV NAT-negative, whereas 8 (24.2%) recipients were HBsAg-positive, indicating chronic infection. Nevertheless, there were no HBV-related Editorial